Industry News

Let's see what's new in the market

Bruker Launches the OMEGA 5 FT-IR Gas Analyzer

Bruker announced the launch of the novel OMEGA 5 Fourier Transform Infrared (FT-IR) based Gas Analyzer. OMEGA 5 allows for automated, high-precision and real-time monitoring of gas concentrations even in complex gas mixtures. It is designed for various applications like process surveillance in production lines, investigation of catalytic processes, determination of gas impurities and scientific research. OMEGA 5 is a 19 inch rackmount box gas analyzer equipped with a multi-reflection gas cell of 5 m optical path length. This gas cell can be heated up to 191°C and pressure as well as temperature of the target gas are automatically displayed and taken into account during the quantification with the gas analysis software OPUS GA. The optics of OMEGA 5 is sealed and purgeable which enables to constantly minimize the concentration of atmospheric interfering compounds like water and carbon dioxide. With the DryPathTM option it is even possible to keep these atmospheric interfering compounds at the lowest level without the need for an external purge gas.

Thermo Fisher Scientific Launches CE/IVD Marked Immunosuppressants Panel for the Cascadion SM Clinical Analyzer

Thermo Fisher Scientific, the world leader in serving science, announced today that it has expanded its European offering of pre-validated assays for the Thermo Scientific Cascadion SM Clinical Analyzer with the addition of the CE/IVD marked Cascadion SM Immunosuppressants (ISD) Panel. Clinical laboratories can now access a complete system developed to enable simultaneous testing of cyclosporine A, everolimus, sirolimus and tacrolimus from a single whole blood sample aspiration using gold standard liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology. The Cascadion analyzer aspirates whole blood directly from qualified, de-capped blood collection tubes without the need for any manual pre-treatment steps. The Cascadion SM Clinical Analyzer with pre-validated assays offers clinical laboratories a fully automated system, providing multiple benefits for boosting laboratory efficiency and productivity. Pre-defined assay parameters and reagents on all Cascadion systems allow for standardization of testing conditions and results, while load up and walkaway operation can be performed by any qualified laboratory personnel with minimal training.

Veredus Laboratories Announces CE-IVD Marking of VereCoV™ Detection Kit for Diagnosis of COVID-19

Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19. The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.

SIGA Announces Collaboration with Turnstone Biologics

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX® (tecovirimat) in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform. The platform utilizes vaccinia viruses engineered for increased selectivity and safety, as well as high-potency immune stimulation, and allows delivery of multiple therapeutic agents directly to tumors. The collaboration will provide Turnstone with access to SIGA’s TPOXX oral antiviral capsules for use if required in future clinical programs. In preclinical studies, TPOXX has been shown to be active against most orthopoxviruses, including vaccinia. The unique mechanism of action of TPOXX coupled with published efficacy in animal studies, make it an important addition to development programs focused on vaccinia-based cancer therapies. On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. TPOXX is the only FDA-approved treatment of smallpox.